Healthcare

Addiction Biotech Cannabis Genetics Healthcare Medical Devices Pharmaceutical Science Veterinary
News Release Digital Asset Direct

GBB Drink Lab Files $53M Lawsuit Against FSD Pharma for Nondisclosure Contract Breach and Trade Secret Misappropriation

GBB Drink Lab

GBB Drink Lab (“GBB” or the “Company”), maker of the world’s first formulated drink that aids in rapid blood alcohol detoxification, has announced that the Company has filed a lawsuit against FSD Pharma (NASDAQ: HUGE) (“FSD”), a publicly traded biotechnology company that operates in the pharmaceutical research and development business. As a result of FSD Pharma’s failure to comply with a Cease-and-Desist letter sent by GBB on April 14 th, 2023, the Company has subsequently filed a $53 million complaint for material breach of a mutual nondisclosure agreement and trade secret misappropriation. Filed on May 1 st, 2023, in the U.S. District Court for the Southern District of Florida, the complaint alleges that after seven months of exploring a business opportunity of mutual interest and benefit revolving around GBB’s blood alcohol detoxification drink, FSD Pharma publicly announced the misappropriation of GBB’s trade secrets to current and prospective investors in one of its press releases. In the press release, FSD Pharma discussed the launch of a new research and development program targeting unmet medical needs for alcohol misuse and deliberately omitted the underlying misappropriation. GBB’s lawsuit alleges that FSD Pharma used GBB’s proprietary and confidential material to raise capital, persuade iconic entrepreneurs to join its advisory board, and drive up the price of FSD Pharma’s publicly traded stock. The Company is seeking compensatory and punitive damages as well as an injunction against FSD Pharma preventing further unlawful disclosure and use of the Company’s trade secrets. The lawsuit has been filed in the U.S. District Court for the Southern District of Florida under the name GBB DRINK LAB, INC. v. FSD BIOSCIENCES INC. with case number: 0:23-cv-60800-AHS. GBB has a patented formula that accelerates the process of converting alcohol to sugar in the body. By enhancing the metabolic pathways that facilitate this process, the formula can help the body clear alcohol much faster than normal. The Company has been working on a proprietary drink for several years using its patented formula. About GBB Drink Lab GBB Drink Lab started with a vision of making a positive impact by offering practical, evidence-based solution to reducing Blood Alcohol Content. The company’s product has been meticulously crafted to optimize your ability to sober up thus enabling you to escape an inebriated state. GBB Drink Lab leadership team includes accomplished serial entrepreneurs, a former senior executive from one of the world’s largest beverage companies, and an industry-leading expert in flavoring science and product formulation. For more information, visit https://gbbdrinklab.com/. Media Contact Jarrett Boon Co-Founder, CEO, GBB Drink Lab, Inc Jarrett@gbbdrinklab.com 602-456-1555 Contact Details GBB Drink Lab Jarrett@gbbdrinklab.com Company Website https://gbbdrinklab.com/

May 05, 2023 08:45 AM Eastern Daylight Time

News Release

1606 Corp launches marketing campaign for CBD singles as it fills gap left by menthol tobacco ban

1606 Corp.

1606 Corp CEO Greg Lambrecht joins Proactive's Stephen Gunnion with details of the company's first major marketing campaign of 2023 focused on menthol-flavored tobacco alternatives in California to address the demand for menthol-flavored smokables following the state’s ban on menthol-flavored tobacco. He says the multi-channel direct marketing campaign, labelled ‘Cali Push,’ is targeted at California merchants, convenience stores, gas stations, liquor stores, and smoke shops which previously stocked menthol-flavored products. The company has enough inventory to place menthol replacement products in more than 2,000 stores immediately, he adds. Contact Details Proactive Investors +1 347-449-0879 na-editorial@proactiveinvestors.com

May 04, 2023 01:25 PM Eastern Daylight Time

Video

News Release

OKYO Pharma reaches milestone with first patient screening for dry eye disease trial

OKYO Pharma Ltd

OKYO Pharma Ltd CEO Gary Jacob tells Proactive's Stephen Gunnion that the first patient has been screened for the phase II trial of OK-101, a treatment for dry eye disease (DED), marking a significant step for the company. Jacob says the phase II trials aims to evaluate the drug's efficacy and safety in DED patients, with top-line data expected before the end of 2023. If successful, he said the phase II assessment could also serve as one of the two required phase III studies necessary for US Food & Drug Administration (FDA) approval. Contact Details Proactive Investors +1 347-449-0879 na-editorial@proactiveinvestors.com

May 04, 2023 01:22 PM Eastern Daylight Time

Video

News Release

Greenlink International announces launch of Suncliff CBD-infused pillow

Greenlink International

Greenlink International CEO Jake George joined Steve Darling from Proactive to share news the company has launched its Suncliff CBD-infused pillow in collaboration with Purecare. George tells Proactive this unique collection features five luxury pillows that incorporate microencapsulated CBD in the fabric, along with a complementary lavender CBD bedding mist to create what they say is a soothing sleep environment. The pillow will be available online and select retail locations in the US in May 2023. Contact Details Proactive Investors +1 604-688-8158 na-editorial@proactiveinvestors.com

May 04, 2023 12:42 PM Eastern Daylight Time

Video

Emergent Health to spin out subsidiary PharmaZu to its Shareholders pursuant to an IPO underwritten by a Nationally Recognized Investment Banking Firm

Emergent Health Corp.

Emergent Health Corp. (OTC: EMGE), a curator, developer, and marketer of products in the Regenerative Health Space announced today that it has executed a Term Sheet for a firm committed underwriting with a nationally recognized investment banking firm for $10,000,000 with respect to planned corporate financing transactions, including the private placement of securities (“pre-IPO Financings”) and the planned $10 million initial public offering of Emergent subsidiary PharmaZu common stock (“IPO”) that will be applied for listing on NASDAQ or NYSE/AMEX, with NO DILUTION to Emergent shareholders. PharmaZu is a pure play, e-commerce products and service provider focused on the Pet Community, Pet Pharmacy and Pet Wellness using Influencers and their content, including pet pharmacy, vet telehealth and pet wellness businesses. Upon the effectiveness of the IPO and listing on a national exchange, PharmaZu plans to acquire a 48-state authorized compounding pharmacy located in West Palm Beach, FL, doing approximately $10M a year in revenue, which will serve as the backbone and fulfilment center for PharmaZu, creating a national platform throughout the United States. Subsequently, Emergent plans to distribute to its shareholders, pro rata, the shares of PharmaZu as a dividend, when a record date is set. The raise of capital will be used for expanding PharmaZu’s business, product offerings, as well as for acquisitions. Jim Morrison, former L'Oréal President and Emergents full time CEO stated, “The transaction with Boustead will start a new exciting chapter for PharmaZu, while maximizing the value to Emergent’s shareholders.” Adam Books, President of PharmaZu stated, “PharmaZu is poised to start its disrupting of the mail order pet business and pet medications, as well as advancing the tele-pet med environment. I am very thrilled to be a part of this.” The execution of the Engagement Letter does not constitute a commitment by Boustead or the Company to consummate any transaction contemplated hereunder and does not ensure the successful placement of securities of any investment vehicle or the success of Boustead with respect to finding any investors or the success with respect to any transaction. No promises, representations or guarantees have been made. ABOUT EMERGENT HEALTH CORPORATION Emergent curates, develops and sells products in the Regenerative Health Space. Its products comprise of ingestibles as well as topicals for the whole family. The company distributes its products online and through Content Based Shopping using Influencers to position products in their produced content throughout the United States and Internationally. Its subsidiaries; PharmaZu, is a pure play, e-commerce products and service provider focused on the Pet Community, Pet Pharmacy and Pet Wellness using Influencers and their content, including the pet pharmacy, vet telehealth and pet wellness businesses; Regen BioWellness, is a distributor of various products in the plant-based and regenerative medical fields. Evolutionary Biologics, is a new kind of biologics company founded for a clear purpose: bring cutting edge regenerative products to the medical community. Emergent does not claim any of its products are approved by the FDA to diagnose, treat, cure or prevent any disease. For more information, please visit Emergent's Website and Social Media on Twitter. Before using any products, you should always consult with your Veterinarian and/or Family Doctor. SAFE HARBOR STATEMENT This press release contains forward-looking statements that can be identified by terminology such as “believes,” “expects,” “potential,” “plans,” “suggests,” “may,” “should,” “could,” “intends,” or similar expressions. Many forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from any future results implied by such statements. These factors include, but are not limited to, our ability to continue to enhance our products and systems to address industry changes, our ability to expand our customer base and retain existing customers, our ability to effectively compete in our market segment, the lack of public information on our company, our ability to raise sufficient capital to fund our business, operations, our ability to continue as a going concern, and a limited public market for our common stock, among other risks. Many factors are difficult to predict accurately and are generally beyond the company's control. Forward-looking statements speak only as to the date they are made, and we do not undertake to update forward-looking statements to reflect circumstances or events that occur after the date the forward-looking statements are made. FOR MORE INFORMATION, PLEASE CONTACT: Jim Morrison, CEO Emergent Health Corporation Website info@emergenthealthcompany.com Contact Details Emergent Health Corp. info@emergenthealthcompany.com Company Website https://emergenthealthcompany.com/

May 04, 2023 09:00 AM Eastern Daylight Time

Image

Doceree Expands Executive Bench with Industry Veterans Marco Parente, Julius Ramirez

Doceree

Doceree, a leading global platform building solutions for healthcare professionals (HCPs) through programmatic messaging with proprietary data tools, has named Marco Parente as EVP Product Management and Julius Ramirez as SVP of Product and Partnership. Parente and Ramirez have joined the U.S. team. The new team members are committed to helping Doceree, which has had robust year-over-year growth, continue its efforts to improve the point-of-care marketing efforts of the pharma industry. “Marco and Julius are talented industry experts who have a deep knowledge of adtech and the role it plays in creating successful campaigns,” said Harshit Jain, global CEO and founder at Doceree. “Their extensive experience with product development and management along with their ability to create lasting global partnerships will support us as we reposition our offerings to deliver the best engagement for our platform partners.” Parente brings more than 20 years of experience in media measurement and market research to his new role in which he is responsible for measurement and identity solutions, product and engineering for Doceree. Prior to joining Doceree, Parente was SVP of product management at Kantar, a leading marketing data and analytics company. He led product partnerships and data integrations for the global media insights business at Kantar. “It is exciting to become a part of Doceree as the company carves new paths for programmatic marketing across the healthcare industry,” Parente said. “The team is dedicated to fostering innovation and leveraging new technologies to improve the industry’s approach to marketing and measurement healthcare, and I’m eager to join Doceree’s transformative efforts.” Ramirez has 25 years of experience in business development and focuses on product and partnership development for Doceree to further strengthen its position as a leading programmatic platform using data, audience targeting, messaging and media planning. Ramirez previously was the head of global partnerships, Meta Audience Network at Meta. There, his focus was on leading strategy and development for the company’s global adtech partnerships. “Doceree has demonstrated tremendous growth through its clear focus on developing solutions to transform healthcare programmatic marketing,“ Ramirez said. “It is amazing to see how Doceree has been able to build a programmatic bridge between healthcare professionals and the pharma industry right when they need it, at the point of care. I am looking forward to helping Doceree to further its efforts to change the way the industry markets to ultimately improve patient care.” About Doceree Doceree is a global platform building unprecedented solutions for healthcare professional (HCP) programmatic messaging with proprietary data tools. It facilitates messaging between life sciences brands and HCPs through an extensive global network of digital endemic and point-of-care platforms to programmatically deliver personalized communications to HCPs and transparent marketing campaign metrics at scale. To learn more, visit doceree.com. Contact Details Kyle Murray +91 70420 89805 kyle@kitehillpr.com Company Website https://doceree.com/us/

May 04, 2023 09:00 AM Eastern Daylight Time

Immunic IMU-856 trial data "clearly goes beyond" initial expectations

Immunic Inc

Immunic Inc (NASDAQ:IMUX) CEO Dr. Daniel Vitt speaks to Thomas Warner from Proactive after releasing new clinical trial data for the biotechnology company's IMU-856 molecule, which is aimed at restoring healthy gut function. The molecule has shown promise in treating celiac disease, with potential applications for other gastrointestinal disorders such as Crohn's disease and ulcerative colitis. Immunic Inc. plans to conduct a Phase 2 clinical trial for IMU-856 in celiac disease patients and explore other potential applications, saying that the phase 1b results "clearly go beyond" initial expectations. Contact Details Proactive United States +1 347-449-0879 action@proactiveinvestors.com

May 04, 2023 08:23 AM Eastern Daylight Time

Video

e-Therapeutics working to capitalise on AI "blindside"

e-Therapeutics PLC

e-Therapeutics PLC (AIM:ETX OTCQX:ETXPF) CEO Ali Mortazavi speaks to Thomas Warner following the release of the computational biology and chemistry company's full year results for 2022. Mortazavi says that it was a "tricky year for the biotechnology sector as a whole" but that eTherapeutics has shown "remarkable resilience." He goes on to highlight the opportunity being presented to the company by the advent of large language models (LLMs) and GPT-4, saying that he's never before seen a technology "blindside the world" to such an extent. Contact Details Proactive UK Ltd Proactive UK Ltd +44 20 7989 0813 uk@proactiveinvestors.com

May 04, 2023 08:20 AM Eastern Daylight Time

Video

Creo Medical Group "knows what it needs to do" after "terrific" 2022

Creo Medical Group PLC

Creo Medical Group PLC (AIM:CREO) CEO Craig Gulliford speaks to Thomas Warner from Proactive after releasing full year results for calendar year 2022 - a year he describes as "terrific" for the endoscopy-focused medical device company. Gulliford also gives the highlights from the post-period, which included an oversubscribed £33.7mln gross fundraise in March of 2023, and says Creo "knows what [it] needs to do" moving forward. Contact Details Proactive UK Ltd +44 20 7989 0813 uk@proactiveinvestors.com

May 04, 2023 08:05 AM Eastern Daylight Time

Video

1 ... 104 105 106 107 108 ... 247